TriangleIvosidenib (NCT06707493)
Ivosidenib trial for IDH1 Mutation (NCT06707493). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged eighteen to seventy-five with IDH1-R132-mutated AML receiving their first donor stem-cell transplant. Maintenance requires no detected leukemia, and blood-count, donor-cell and graft-versus-host-disease requirements apply.
The idea: compare daily oral ivosidenib with placebo, starting forty-five to ninety days after transplantation for up to two years. Ivosidenib blocks mutant IDH1, which may allow abnormal cells to mature. Researchers measure whether it delays relapse or death. Transplant care remains standard.
This phase 2 study plans 75 patients. Massachusetts General Hospital's Amir Fathi leads seven recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.